VK2735
4 articles on VK2735, researched and written by the Shotlee Editorial Team from primary sources.
Wegovy & Mounjaro Boom Fuels Peptide Production Surge for GLP-1 Drugs
The unprecedented demand for GLP-1 medications like Ozempic, Wegovy, Mounjaro, and Zepbound is triggering a significant global expansion in peptide manufacturing. Learn how key players are investing billions to meet the surging need for these life-changing therapies.
7 min read
Novo Nordisk Stock Erases Wegovy Gains After CagriSema Miss
Novo Nordisk's stock has erased the last of its Wegovy-driven gains in a brutal week, down 21% after next-gen obesity drug CagriSema underperformed rivals. Despite 20.2% weight loss in trials, analysts downgrade amid patent cliffs and competition from Eli Lilly's tirzepatide. The company's pivot to oral Wegovy offers hope, but diversification pressures mount.
5 min read
Viking Therapeutics Shares Surge 12% as Novo's CagriSema Stumbles
Shares of Viking Therapeutics surged approximately 12% on Monday following a clinical setback for Novo Nordisk's next-generation obesity drug CagriSema, which underperformed Eli Lilly's Tirzepatide in a pivotal Phase 3 trial. This shift highlights intensifying competition in the GLP-1 obesity market. Investors are eyeing Viking's VK2735 as a promising contender.
5 min read
Viking Therapeutics Stock Surges on VK2735 Trial Success
Viking Therapeutics stock closed at $34.34, up 11.44%, fueled by VK2735 Phase 2 success. The trial delivered 14.7% average weight reduction, challenging GLP-1 leaders like Ozempic. Acquisition speculation boosts investor interest.
1 min read